Shore Capital Partners
Shore Capital Partners states that it invests in lower-middle-market companies across healthcare, food and beverage, real estate, business services, and industrials. Its stated model combines founder partnerships, board and executive recruitment, operational support, and acquisition-led growth; its healthcare funds describe control equity investments in specified healthcare markets.
What stands out about Shore Capital Partners
Shore Capital Partners publicly describes platform investments of $5–$100m in revenue and $1–$10m in EBITDA, with add-on investments of $1m+ in revenue and no minimum EBITDA requirement. Its healthcare materials describe separate fund criteria, including platform revenue ranges of $100M+ and $5-$200M, depending on the fund.[1][2][3][5][6][9]
What does Shore Capital Partners invest in?
Shore Capital Partners is a Chicago-based private equity firm with an office in Nashville that invests in lower-middle-market companies.
Shore describes its process as “research, recruit, partner, and grow.” The stated approach includes industry research, board and executive recruitment, founder partnerships, capital, operational support, and growth initiatives.[1][2]
Shore states that it uses a research-led buy-and-build strategy focused on fragmented industries. Its materials describe support for both organic growth and acquisition growth.
For healthcare, Shore describes control equity investments in healthcare services, payor services, products, and distribution markets. It targets proven private companies with strong management teams, stable cash flow, and significant growth potential.[2][3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Shore Capital Partners?
An owner evaluating Shore should compare the company’s profile with the applicable platform or add-on criteria and identify which sector and fund mandate would apply. Shore’s stated model includes founder partnerships, board and executive recruitment, operational support, and acquisition growth; its healthcare materials describe control equity investments in specified healthcare markets.
Owners should clarify control and voting rights, rollover equity, governance, management continuity, add-on acquisition expectations, fee allocation, and ownership-duration objectives. The Texas MedClinic and Mission Pet Health announcements do not provide all economic terms, and Shore’s general investment-approach page does not state an expected ownership duration or holding-period range.[2][3][5][6]
What percentage of equity and voting control would Shore seek, and what rollover-equity range would be expected
What ownership duration, exit options, and recapitalization policies apply to the proposed investment
What companies does Shore Capital Partners target?
Shore’s general investment profile states that platform investments are directed toward companies with $5–$100m in revenue and $1–$10m in EBITDA. It states that add-on investments may involve companies with $1m+ in revenue and no minimum EBITDA requirement.
Healthcare criteria vary by stated fund. The Healthcare Advantage Fund lists platform criteria of $100M+ in revenue and $10M-$50M in EBITDA. Shore Capital Healthcare Partners Fund lists platform criteria of $5-$200M in revenue and $1M-$10M in EBITDA. Both list add-on investments of $1M+ in revenue with no EBITDA requirements.[2][3]
Shore states that it is actively investing in healthcare, food and beverage, real estate, business services, and industrials.
Its stated healthcare focus areas include bioanalytical services, lab services, home health and hospice, applied behavior analysis, medical-device outsourcing, healthcare cost containment, revenue-cycle management, healthcare marketing, pharma commercialization, and clinical-trial support services, among other listed subsectors.[2][3]
Shore lists offices at 1 East Wacker Drive, Suite 2900, Chicago, Illinois, and 1600 West End Avenue, Suite 1950, Nashville, Tennessee.[1]
Shore describes a model in which it identifies fragmented growth niches, partners with founders or entrepreneurs to launch platform companies, and supports organic and acquisition growth.
The general investment profile distinguishes platform investments from add-on investments. Platform criteria are stated at $5–$100m in revenue and $1–$10m in EBITDA, while add-on criteria are stated at $1m+ in revenue with no minimum EBITDA requirement. Healthcare fund materials state additional platform ranges by fund and the same $1M+ add-on revenue threshold with no EBITDA requirements.[2][3]
Shore’s companies page lists 64 current investments, 23 realized investments, and 87 total companies. The page lists 56 healthcare, 15 food and beverage, 10 business services, and 6 industrials companies.
Separately, Shore’s investment-approach page reports 87 platform companies, approximately $17B in assets under management, and 23 realized investments.[2][4]
Shore announced on August 14, 2026 that Shore-backed Community Care Partners completed the sale of Texas MedClinic to HCA Healthcare. The announcement states that Texas MedClinic had 40 locations and was acquired by Community Care Partners in 2022.
Shore announced on July 17, 2026 the sale of 102 Mission Pet Health veterinary properties held by Shore Capital Real Estate Partners Fund I to Four Corners Property Trust for approximately $268 million. The transaction closed July 16, 2026.
On January 22, 2026, Shore announced the launch of Maintera Facility Services and its acquisition of Commercial Asset Preservation. The announcement states that Maintera followed Shore’s December 2024 investment in TCG Services.[5][6][7]
What is not clear from Shore Capital Partners's public investment criteria?
Shore’s terms page states that website transactional and statistical information, including assets under management, relates in whole or in part to specified operating platforms. The same page states that Sweetmore, Mission Pet Health, and BrightView are not fund or advisory clients of Shore Capital.
The Texas MedClinic transaction announcement does not disclose sale consideration, financing terms, rollover equity, or other economic terms. The Mission Pet Health real-estate transaction announcement does not disclose seller rollover equity, financing terms, or fund-level return metrics beyond the approximately $268 million purchase price.
Shore’s general investment-approach page states its general revenue and EBITDA profile but does not state an expected ownership duration or holding-period range.[2][5][6][9]
Questions to ask when evaluating Shore Capital Partners as a buyer or investment partner
Which fund or investment platform would invest, and which platform or add-on criteria would apply?
What percentage of equity and voting control would Shore seek, and what rollover-equity range would be expected?
What ownership duration, exit options, and recapitalization policies apply to the proposed investment?
How are management fees, transaction fees, monitoring fees, and portfolio-company expenses allocated?
What board seats, reserved matters, and operating-partner resources would apply?
Sources & research notes
- Official website / firm overview
- Services / capabilities
- Industry / market focus
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- SEC filing / regulatory record
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.